Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of ARTHEx Biotech.

    Client Virtual Booth

    ARTHEX BIOTECH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    ARTHEx Biotech
    Spain_new Flag
    Country
    Country
    Spain
    Address
    Address
    C/ Catedrático Agustín Escardino 9 46980 Paterna, Valencia
    Telephone
    Telephone
    +34 625 016 629
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.arthexbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/arthex-pharma/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

    Details:

    ATX-01, an antimiR designed to target microRNA 23b (miR-23b), is the first microRNA therapeutic which is being evaluated for the treatment of Myotonic Dystrophy Type 1.


    Lead Product(s): ATX-01

    Therapeutic Area: Genetic Disease Product Name: ATX-01

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 28, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)

    Details:

    The Series B proceeds will be used to advance company's lead compound, ATX-01 (amitriptyline hydrochloride), an antimiR designed to target microRNA 23b (miR-23b), to a Phase I/IIa clinical trial for the treatment of Myotonic Dystrophy Type 1 (DM1).


    Lead Product(s): ATX-01

    Therapeutic Area: Neurology Product Name: ATX-01

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Columbus Venture Partners

    Deal Size: $46.4 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing May 03, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arthex Announces Regulatory Milestones Met in Its Program to Develop ATX-01 in Myotonic Dystrophy Type 1

    Details:

    ATX-01 is an investigational drug compound designed to address myotonic dystrophy, a rare progressive muscle wasting disease, by targeting a microRNA involved in the disease pathogenesis.


    Lead Product(s): ATX-01

    Therapeutic Area: Genetic Disease Product Name: ATX-01

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 14, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arthex Biotech Selected for EIC Accelerator Award of up to 14 Million Euros

    Details:

    Proceeds will be used to fund the FIGHT-DM 1 project to initiate clinical trial of Arthex' lead candidate, ATX-01, in DM1 in 2023.


    Lead Product(s): ATX-01

    Therapeutic Area: Genetic Disease Product Name: ATX-01

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: EIC Accelerator

    Deal Size: $13.7 million Upfront Cash: Undisclosed

    Deal Type: Funding October 25, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search